PharmaCielo Past Earnings Performance
Past criteria checks 0/6
PharmaCielo has been growing earnings at an average annual rate of 16.2%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 39.7% per year.
Key information
16.2%
Earnings growth rate
29.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 39.7% |
| Return on equity | -460.1% |
| Net Margin | -456.0% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Is PharmaCielo (CVE:PCLO) Using Too Much Debt?
Oct 04
Is PharmaCielo (CVE:PCLO) Using Too Much Debt?
Feb 25PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt
Aug 03Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load?
Dec 23Is PharmaCielo (CVE:PCLO) A Risky Investment?
May 14Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit?
Feb 16Revenue & Expenses BreakdownBeta
How PharmaCielo makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 3 | -13 | 10 | 0 |
| 30 Jun 23 | 3 | -15 | 11 | 0 |
| 31 Mar 23 | 5 | -15 | 12 | 0 |
| 31 Dec 22 | 5 | -15 | 12 | 0 |
| 30 Sep 22 | 4 | -16 | 12 | 0 |
| 30 Jun 22 | 4 | -19 | 15 | 0 |
| 31 Mar 22 | 2 | -23 | 17 | 0 |
| 31 Dec 21 | 2 | -27 | 20 | 0 |
| 30 Sep 21 | 2 | -42 | 31 | 0 |
| 30 Jun 21 | 2 | -43 | 31 | 0 |
| 31 Mar 21 | 3 | -44 | 33 | 0 |
| 31 Dec 20 | 3 | -44 | 34 | 0 |
| 30 Sep 20 | 2 | -36 | 29 | 0 |
| 30 Jun 20 | 3 | -30 | 29 | 0 |
| 31 Mar 20 | 1 | -33 | 32 | 0 |
| 31 Dec 19 | 1 | -35 | 30 | 0 |
| 30 Sep 19 | 0 | -31 | 28 | 0 |
| 30 Jun 19 | 0 | -36 | 33 | 0 |
| 31 Mar 19 | 0 | -29 | 27 | 0 |
| 31 Dec 18 | 0 | -32 | 31 | 0 |
| 31 Dec 17 | 0 | -16 | 15 | 0 |
| 31 Jul 17 | 0 | -9 | 9 | 0 |
| 31 Jul 16 | 0 | -11 | 7 | 0 |
Quality Earnings: PCLO is currently unprofitable.
Growing Profit Margin: PCLO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCLO is unprofitable, but has reduced losses over the past 5 years at a rate of 16.2% per year.
Accelerating Growth: Unable to compare PCLO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCLO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.4%).
Return on Equity
High ROE: PCLO has a negative Return on Equity (-460.14%), as it is currently unprofitable.